Presight Capital

Presight Capital is the international venture arm of Apeiron Investment Group, founded in 2019. The firm invests in founders worldwide across the full company-building arc, from seed through IPO, covering both early-stage and growth opportunities. Cheques range from $500,000 to $20 million per company, a span that allows participation in initial rounds as well as follow-on and later-stage financings within the same portfolio.

The investment focus is weighted towards deep technology and life sciences. Areas of activity named by the firm include antibody drug discovery, computational drug discovery, mental health treatments, brain technologies, heart disease diagnosis, fusion energy and industrial robotics, alongside consumer products. The pattern suggests a mandate defined by the technical depth of the problem rather than a single sector or geography: Presight describes its approach as global and multi-sector, backing ambitious founders tackling consequential challenges and providing capital together with support to build lasting companies.

For candidates, the relevant characteristics are the firm's dual-stage posture - spanning seed and growth rather than a single entry point - and its concentration in science- and engineering-heavy domains such as biotechnology, neurotechnology and energy. Founded in 2019, Presight operates as the international investing platform of a single family office group, Apeiron Investment Group, rather than as an institutional fund manager with disclosed outside limited partners.